FDA
-
-
-
-
-
-
-
Spruce Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Updates
-
-
-
-
-
-
-
Spruce Biosciences (SPRB) Announces New Corporate Strategy and Acquisition of Tralesinidase Alfa for the Treatment of Sanfilippo Syndrome Type B
-
-
-
-
-
-
-
Ladenburg Thalmann Downgrades Spruce Biosciences, Inc. (SPRB) to Neutral, 'Regulatory Path Unclear'
-
-
-
-
-
-
-
Spruce Biosciences Reports First Quarter 2021 Financial Results and Provides Corporate Updates
-
-
-
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

